The filing for sitagliptin tablets in three strengths marks Morepen’s entry into integrated finished-dose development and regulatory filings in the US market
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.